Nastech Pharmaceuticals - Worst Pharma Stocks of 2007
Company:Â Nastech PharmaceuticalsÂ
Starting stock price: $14.68
Ending stock price: $3.80
Percent Change: -74.11%
Details: Early in 2007 Merck announced that a preliminary study of Nastech's PYY3-36 anti-obesity spray demonstrated no effect and was pulling out of a collaboration to develop the therapy. Then, in November, Nastech took another serious hit after Procter & Gamble pulled out of its efforts on an osteoporosis nasal spray treatment. The company has since announced plans to restructure, including plans to lay off some of its 197 workers.
More News:
Nastech spins off RNAi unit, restructures. Report
Nastech shares wilt after P&G returns drug rights. Report
Nastech to push ahead with obesity spray trial. Report
Nastech hit on missed payment. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: